We are investigating whether the directors of LHC Group, Inc. (ticker: LHCG) (“LHCG”) acted in the best interests of LHCG shareholders in approving the sale of LHCG to Optum Health (“Optum”) for $170.00 per share in cash.
If you remain an LHCG shareholder and have questions about your legal rights, please contact our firm via the form below to discuss your options at no charge.
Why is there an investigation?
On March 29, 2022, LHCG announced an agreement for Optum to purchase all of the outstanding shares of LHCG for $170.00 per share in cash.
Our investigation concerns whether LHCG’s board acted in the best interests of LHCG shareholders in approving the sale to Optum, including whether the acquisition price adequately compensates LHCG shareholders, and whether all material information regarding the transaction has been fully disclosed.
In particular, according to an analysis of Wall Street price targets for LHCG in the last 90 days published on Seeking Alpha, there is a high price target for LHCG of $190.00 per share.
Additionally, Optum is owned by UnitedHealth Group Incorporated (ticker: UNH) (“UNH”). As part of the transaction, LHCG’s founders, Keith and Ginger Myers, will personally invest $10 million in UNH stock following the close of the transaction.